{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:41:44Z","timestamp":1784698904530,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20209003"],"award-info":[{"award-number":["3502Z20209003"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20209008"],"award-info":[{"award-number":["3502Z20209008"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170180"],"award-info":[{"award-number":["82170180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000218"],"award-info":[{"award-number":["82000218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J011246"],"award-info":[{"award-number":["2020J011246"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J01222713"],"award-info":[{"award-number":["2020J01222713"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.critrevonc.2022.103756","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T19:45:50Z","timestamp":1657136750000},"page":"103756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis"],"prefix":"10.1016","volume":"176","author":[{"given":"Zhijuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2022.103756_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-013-0520-0","article-title":"Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center","volume":"30","author":"Avil\u00e9s","year":"2013","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0097-0","article-title":"CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies","volume":"8","author":"Ayed","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2022.103756_bib3","article-title":"P05.04 Phase 2 open-label study of maintenance treatment with ibrutinib following first line methotrexate-based immuno-chemotherapy in elderly patients with primary CNS lymphoma (PCNSL)","volume":"21","author":"Bairey","year":"2019","journal-title":"Neuro-Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103756_bib4","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/bloodadvances.2021004766","article-title":"Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP","volume":"5","author":"Bernard","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103756_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J."},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103756_bib6","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103756_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol."},{"issue":"SUPPL 2","key":"10.1016\/j.critrevonc.2022.103756_bib8","first-page":"220","article-title":"Intravenous high dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma (DLBCL): Real-world outcomes and practice patterns from Chinese institution","volume":"5","author":"Cai","year":"2021","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40880-016-0150-y","article-title":"New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study","volume":"35","author":"Cai","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib10","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2017.040","article-title":"Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-Cell lymphoma","volume":"9","author":"Cencini","year":"2017","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103756_bib11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103756_bib12","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3109\/10428194.2011.596966","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model","volume":"52","author":"Chihara","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","article-title":"How I treat patients with aggressive lymphoma at high risk of CNS relapse","volume":"130","author":"Chin","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103756_bib14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103756_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12185-013-1458-x","article-title":"Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era","volume":"98","author":"Deng","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103756_bib16","unstructured":"Dias, S., N.J. Welton, A.J. Sutton, et al., in NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2014: London."},{"key":"10.1016\/j.critrevonc.2022.103756_bib17","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome","author":"Dodero","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2022.103756_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","article-title":"The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy","volume":"75","author":"El-Galaly","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103756_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.16070","article-title":"Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity","volume":"187","author":"Eyre","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib20","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","article-title":"Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review","volume":"105","author":"Eyre","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.13194","article-title":"Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"168","author":"Ferreri","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103756_bib23","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(21)00022-3","article-title":"Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial","volume":"8","author":"Frontzek","year":"2021","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103756_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103756_bib25","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","article-title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","volume":"28","author":"Gleeson","year":"2017","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103756_bib26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1080\/10428194.2018.1564823","article-title":"Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse","volume":"60","author":"Goldschmidt","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103756_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature","volume":"159","author":"Guirguis","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2022.103756_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103507","article-title":"Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: a systematic review and meta-analysis","volume":"167","author":"Ho","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103756_bib31","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1111\/cas.13828","article-title":"Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure","volume":"109","author":"Hu","year":"2018","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103756_bib32","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/bloodadvances.2020003947","article-title":"Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis","volume":"5","author":"Jeong","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103756_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL","volume":"133","author":"Klanova","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103756_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era","volume":"176","author":"Kridel","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103756_bib35","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12185-019-02653-7","article-title":"Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis","volume":"110","author":"Lee","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/ejh.12626","article-title":"Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study","volume":"96","author":"Lemma","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103756_bib38","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Lepp\u00e4","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2022.103756_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2019.04.004","article-title":"Intravenous but not intrathecal central nervous system\u2013directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma","volume":"115","author":"Mannisto","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103756_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2141.2011.08998.x","article-title":"The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma","volume":"157","author":"Mitrovic","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib41","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","article-title":"CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab","volume":"22","author":"Miyazaki","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103756_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103756_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103756_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-021-00535-y","article-title":"High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma","volume":"11","author":"Ong","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2022.103756_bib45","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions","author":"Orellana-Noia","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib46","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3324\/haematol.2018.195834","article-title":"Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma","volume":"104","author":"Qualls","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103756_bib48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ejh.13667","article-title":"Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"107","author":"Renaud","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103756_bib49","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3324\/haematol.2021.278559","article-title":"Preventing central nervous system spread in diffuse large B-cell lymphoma \u2013 novel approaches needed","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103756_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2022.103756_bib51","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib52","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mdr440","article-title":"CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"23","author":"Schmitz","year":"2012","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103756_bib53","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","article-title":"Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience","volume":"89","author":"Shimazu","year":"2009","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103756_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-142299","article-title":"Patterns and Risk of CNS recurrence after R-EPOCH treatment for double\/triple hit lymphoma","volume":"136","author":"Sohail","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103756_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib57","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","article-title":"Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab","volume":"90","author":"Tai","year":"2011","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103756_bib58","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-Cell lymphoma treated With first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2022.103756_bib59","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103756_bib60","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103756_bib61","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103756_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25723","article-title":"Intravenous methotrexate at a dose of 1 g\/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: a prospective, historic controlled study","volume":"95","author":"Wang","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103756_bib63","unstructured":"Wells G., S.B., O\u2019Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. 2013; Available from: \u3008http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\u3009."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103756_bib64","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/bloodadvances.2020002421","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery","volume":"4","author":"Wilson","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103756_bib65","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00277-016-2848-y","article-title":"Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry","volume":"96","author":"Wudhikarn","year":"2017","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103756_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2010.01438.x","article-title":"Central nervous system involvement in diffuse large B-cell lymphoma","volume":"85","author":"Yamamoto","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103756_bib68","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines(R) insights: B-Cell lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103756_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/10428194.2013.811239","article-title":"Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-Analysis","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk. Lymphoma"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:44:10Z","timestamp":1760903050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":69,"alternative-id":["S1040842822001809"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103756","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103756"}}